FDA approves new option amid COVID-19-spurred sedation drug shortages
The Food and Drug Administration this week approved dexmedetomidine hydrochloride in 0.9% sodium chloride injection for the sedation of initially intubated and mechanically ventilated patients in an intensive-care setting and of non-intubated patients prior to and/or during surgical and other procedures.
The drug helps address short supplies of sedation options due to the COVID-19 public health emergency. Side effects of the drug include low blood pressure, slow heart rate and dry mouth.
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…